Soluble β-glycan/TβRIII mainly activates TGF-β2-Smad signaling and the expression of TβRIII reduces the anti-tumor function of TGF-β2 in clear-cell renal cell carcinoma. This evidence concerns the gene TGFB2 and clear cell renal carcinoma.